This is quite likely short term exit and bored attempt in trading but I sold 300 shares of NexGen Energy for 5,40 CAD per share. These shares were bought in 2,07-2,21 CAD range. Uranium sector is likely to provide plenty of volatility but mid and long term vision is still intact. Therefore I might buy back these shares later. Then again I’m interested in simplifying the portfolio by focusing more on the main strategy. Let’s see how coming months play out.
Recent Buy: Kemira Oyj
Once again maintenance purchase with 20 Kemira shares bought for 12,19 EUR per share. Nothing special here as this is one addition to the long list of similar purchases. However, my cash reserves have reached my soft limit so I should really make bigger moves but gut feeling has prevented it lately. I’ll have to keep an eye on this topic but if my gut keeps complaining I’ll just make these maintenance purchases and re-invest dividends. In general holding cash might be a bit bad idea but my personal inflation level is very different. Therefore inflation does not hurt me quite as much as most people.
Sold: UEX Corporation
I decided to sell my tiny UEX position of 1500 shares. I never got around building a bigger position on it and therefore decided to sell now since the position is way too small to motivate tracking buyout offers from Uranium Energy Corp and Denison Mines Corp. I bought these shares for 0,220 CAD per share and sold now for 0,47 CAD per share. Nice enough gain of 139% but somewhat insignificant amount of dollars.
Recent Buy: 3M Co.
Dividend re-investment in lack of better ideas: 10 shares of 3M for 129,90 USD per share. Sure, company is facing all kinds of issues ranging for legal problems to overall inflation environment. I don’t really focus a lot on those with these huge companies. These kind of issues will come and go. Sometimes they might end up being fatal or close to it but most of the time companies will adapt and move on.
Recent Buy: Kemira Oyj
Just a tiny maintenance purchase of 10 shares of Kemira bought for 11,77 EUR per share. Nothing new here as this is just a maintenance purchase done for two reasons: consistently buying something and to avoid fees.
Q2/2022 Results
Another wild quarter has passed. Global economy is still facing pretty much same issues: COVID-19 tails, war in Ukraine and inflation/interest rate issues. On the positive side Finland and Sweden were finally invited to become NATO members but I’m sure Turkey will have additional tricks to use when the process moves forward. I personally don’t see huge risks in this as long as critical member states ratify the membership. This is very positive development in otherwise dire situation. Pandemic can of course take new directions and there’s also the monkeypox situation going on but probably this is something than will keep on fading into the background noise. War in Ukraine seems to be evolving in a positive way, or at least West and rest of the world has been providing enough resources for Ukraine to defend themselves. Russia is bleeding but probably this will take a long time to truly play out. Then there’s the inflation and interest rate issue where ECB seems to be late – as usual – on everything. FED seems to be doing a bit better but I guess situation is far from ideal in US as well.
On personal side this quarter was solid bounce year over year. Market overall has been taking a beating but my portfolio has performed reasonably well as main portfolio only dropped 1.45% during the quarter. Compared to to overall market this is partially explained by the fact that my portfolio bounced back from COVID-19 impact way slower in general. Bounce back was even more visible with received dividends. Q2 dividends before taxes were 5715,66 EUR compared to 2684.31 EUR year before.
What’s next then? I have allowed my cash buffer to grow lately and done some purchases, mainly as dividend re-investments and smaller maintenance purchases. This is likely to continue while waiting for for bigger opportunities. I still have pharma and medical sectors on my radar so I might still add on Abbvie and Gilead Sciences but I might also open a position in Medtronic. Let’s see how things evolve.
Recent Buy: Investor AB, Castellum AB and Cibus Nordic Real Estate AB
Market has been quite red lately and for good reason. Inflation is getting out of hand, central banks are more or less behind the curve, war in Ukraine is far from being over, food might be in short supply and list goes on and on. It might still be too early to make any moves but I decided to initiate positions on companies mentioned in the subject. These are not significant positions and were more or less dividend reinvestments with existing SEK balance. This also increases both my exposure in Swedish stocks and SEK dividend income. Both are strategic long term choices given my location and home currency. I would consider these purchases as controlled risk as I consider the likelihood of either short term inflation or inability of central banks (European or Swedish) to make necessary (rate) changes high enough but let’s see how these will eventually play out.
- Castellum AB 100 shares for 145,20 SEK per share
- Cibus Nordic Real Estate AB 70 shares for 188,90 SEK per share
- Investor AB (B series) 80 shares for 172,38 SEK per share
Recent Buy: Kemira Oyj
Maintenance purchase or more like a dividend re-investment with a purchase of additional 20 shares of Kemira. This time I paid 11.90 EUR per share. Still nibbling on until situation calls for bigger purchases.
Recent Buy: Gilead Sciences, Inc.
As anticipated for the second quarter, I initiated a new position on Gilead Sciences, Inc. with a purchase of 25 shares bought for 60,53 USD per share. This complements the other pharmaceuticals (AbbVie and Pfizer) and a bit more riskier one. Company financials are not ideal (debt and all) but then again valuation seems to be reflecting it quite nicely. Then again virus focused company is quite nice addition considering how to company is positioned for the ongoing decade. I’m not sure if I will build a full position with any of these companies. Instead I might just handle all of them as a basket of pharmaceuticals filling that position in the portfolio. Might even eventually add few additional ones but let’s see.
Q1/2022 Results
Another quarter passed and what a ride it was once again. Russian special operation – Njet problem, normal katastrof – in Ukraine kicked in and outcome was probably something most didn’t expect. Ukraine has put on a brave fight and now this one month old war (well, in reality it began years ago with the annexation of Crimea) is turning into a real shit show for Russians. Economic sanctions on Russia are something that I for one didn’t expect international community ever to pull off. Russia is like zombie with the exception of zombie having fair chance of eating before rotting away. This all hit some companies really hard but overall markets way less than I would have guessed. On personal level impact could be described as minor mainly due to having very limited Russian exposure and elevated US exposure. It’s hard to estimate how this thing will play out. Hopefully international community will not scale down the sanctions until Russia truly learns the provided free lesson. Furthermore this will hopefully result Finland joining NATO. This is something that should have been done in the 1990’s but better late than never. This would be extremely important also to mitigate country risk associated in being small open economy next door to Russia.
Main portfolio gained about 7% during the quarter. Dividend income was 1623,60 USD dollars and 120 EUR before taxes or 1566,42 EUR when using the exchange rate at the time of writing. Quite solid improvement compared to 1190,15 EUR year ago.
What next? Overall bounce back from the Russian special financial operation was maybe too quick. Inflation fears are still there and underlying problems in global economy are probable just one month older and equally bigger. Most likely I will just continue with current approach: do mainly smaller purchases and re-invest dividends. Let cash position grow a bit even though it’s quite significant already and not really ideal considering the inflation environment. Then again my personal finances are less severely hit by inflation as my consumption level is in general low and key factors like energy are either low or something that I can almost eliminate if and when needed. Let’s see. I might initiate a new position on Gilead Sciences and possibly add on existing 3M and Kemira positions while waiting for better opportunities to make bigger moves.